Lantern Pharma Inc SEC Filings

Lantern Pharma (LTRN) director Vijay Chandru amended two outstanding stock options on 09/19/2025, replacing earlier awards with new options priced at $5.04 per share. The original options were granted on 06/15/2020 (9,135 underlying shares, originally $15 exercise price, expiration 06/14/2030) and 11/04/2021 (3,200 underlying shares, originally $10.32 exercise price, expiration 11/03/2031). The amendments cancelled the old options and granted replacement options covering the same share amounts, leaving Mr. Chandru with options for a total of 12,335 underlying shares exercisable under the stated expirations.

Panna Sharma, President & CEO and a director of Lantern Pharma Inc. (LTRN), amended an outstanding stock option originally granted on 06/15/2020. The amendment, recorded with a transaction date of 09/19/2025, canceled the prior option with a $15 exercise price covering 76,628 underlying shares and replaced it with a new option covering the same 76,628 shares at a reduced exercise price of $5.04. The option retains its original exercisability and expiration schedule (vested schedule described in the filing) and the replacement option shows 76,628 shares beneficially owned following the amendment. The form is signed by Ms. Sharma on 09/22/2025.

Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), filed a Form 4 reporting amendments to previously granted stock options. The filing shows two option amendments: a June 15, 2020 option was cancelled and replaced with a $5.04 exercise-price option covering 52,200 shares exercisable through 06/14/2030; a October 29, 2021 option was cancelled and replaced with a $5.04 exercise-price option covering 17,400 shares exercisable through 10/28/2031. After the replacements, Mr. Bhatia beneficially owns 52,200 and 17,400 underlying common shares for the respective options.

D. Jeffrey Keyser, a director of Lantern Pharma Inc. (LTRN), reported amendments to two outstanding stock options on a Form 4 covering transactions dated 09/19/2025. Each amendment cancelled an "old" option and granted a replacement option with a reduced exercise price while retaining the original grant dates and expiration dates. The June 15, 2020 option for 9,135 shares was changed from a $15.00 exercise price to $5.04 and remains exercisable through 06/14/2030. The November 4, 2021 option for 3,200 shares was changed from a $10.32 exercise price to $5.04 and remains exercisable through 11/03/2031. Both options vest on the original monthly 36-month schedules.

Lantern Pharma director and Chief Financial Officer David R. Margrave reported amendments to two previously granted stock options that reduced the exercise prices and replaced the canceled options with new options. One option originally granted June 15, 2020 for 78,300 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 06/14/2030, resulting in a held position of 78,300 underlying shares. A second option originally granted October 29, 2021 for 26,100 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 10/28/2031, resulting in a held position of 26,100 underlying shares. The filing is limited to these option amendments and the reporting person’s relationship as Director and Chief Financial Officer.

Lantern Pharma Inc. (LTRN): Director David S. Silberstein reported amendments to two outstanding stock options on 09/19/2025 that reduced the exercise prices and replaced the prior options. The first option originally granted 06/15/2020 (exercise price $15) for 9,135 shares was cancelled and replaced with a $5.04 option exercisable through 06/14/2030, leaving 9,135 underlying shares beneficially owned. The second option originally granted 11/04/2021 (exercise price $10.32) for 3,200 shares was cancelled and replaced with a $5.04 option exercisable through 11/03/2031, leaving 3,200 underlying shares beneficially owned. The filings note standard monthly vesting schedules for each original grant and the form is signed 09/22/2025.

Lantern Pharma (LTRN) director Lee T. Schalop was granted a stock option award for 5,000 shares under the companys Amended and Restated 2018 Equity Incentive Plan. The option has an exercise price of $4.46 and was granted with a transaction date of 08/19/2025. The award becomes exercisable in equal monthly increments over a 36-month vesting period commencing 09/19/2025 and expires 08/18/2035. The filing reports 5,000 underlying shares held directly following the grant. The Form 4 was submitted by the reporting person, who is identified as a director of the issuer.

Lantern Pharma Inc. reported in a Current Report on Form 8-K dated August 13, 2025 that it will issue a press release announcing its financial results for the second quarter ended June 30, 2025. The Company furnished the press release as Exhibit 99.1 and included a cover page interactive data file as Exhibit 104.

The filing notes the disclosure is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other filings. The document identifies Lantern Pharma as an emerging growth company, indicates it elected not to use the extended transition period for new accounting standards, lists its Nasdaq ticker LTRN, principal executive office in Dallas, Texas, and is signed by CFO David R. Margrave.

Lantern Pharma Inc. (LTRN) reported continuing operating losses as it advances three clinical-stage small-molecule candidates and an ADC program while relying on its RADR^® A.I. platform. For the six months ended June 30, 2025, the company recorded a net loss of $8,867,798 versus $10,400,316 a year earlier, and net loss per share of $0.82 versus $0.97. Cash and cash equivalents were $6,061,408 and marketable securities were $9,840,366, giving approximately $15.9 million of combined liquidity and working capital of about $12.3 million.

The company noted a substantial doubt about its ability to continue as a going concern absent additional financing but expects existing resources to fund operations into June 2026. In July 2025 Lantern entered an ATM Sales Agreement to offer up to $15.53 million of common stock and sold 15,185 shares for approximately $80,000 through August 12, 2025. Research and development expense decreased to $6.33 million for the six months ended June 30, 2025 from $8.14 million a year earlier, while general and administrative expense was roughly stable at about $3.09 million. The company continues active clinical programs for LP-300 (Phase 2), LP-184 (Phase 1) and LP-284 (Phase 1) and operates the RADR platform and a Starlight subsidiary for CNS development.